Final results from the randomized phase 2 trial of trastuzumab deruxtecan in patients with HER2-mutant NSCLC were reported at ASCO 2024 and summarized in this video by Amanda L. Brink, DNP, APRN, FNP-BC, AOCNP. She recaps the efficacy and safety data while highlighting the importance of nurses in assessing and managing adverse events associated with these medications.
Amanda L. Brink, DNP, APRN, FNP-BC, AOCNP Advanced Practice Registered Nurse Department of Investigational Cancer Therapeutics Division of Cancer Medicine The University of Texas MD Anderson Cancer Center Houston, TX
Sponsored by
To sign up for our newsletter or print publications, please enter your contact information below.
